Robinson Chandler, CEO of Monopar Therapeutics ($MNPR), made one open market sale of common shares in the last year, totaling $672 thousand. His most recent sale occurred on July 14, 2025. These sales rank 5,839th among 11,678 insiders in our database, well below the average of $8.6 million per insider and 6.4 transactions. He had no open market purchases during this period.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| March 31, 2026 | Monopar Therapeutics | $MNPR | Robinson Chandler | Chief Executive Officer | M | Common Stock | 6732 | $0.00 | 155,265.0000 | 6,662,930 | 4.53% | 0.10% |
| March 31, 2026 | Monopar Therapeutics | $MNPR | Robinson Chandler | Chief Executive Officer | F | Common Stock | 1972 | $54.79 | 153,293.0000 | 6,662,930 | 1.27% | 0.03% |
| March 31, 2026 | Monopar Therapeutics | $MNPR | Robinson Chandler | Chief Executive Officer | M | Restricted Stock Unit | 6732 | $0.00 | 106,276.0000 | 6,662,930 | 5.96% | 0.10% |
| Jan. 28, 2025 | Monopar Therapeutics | $MNPR | Robinson Chandler | Chief Executive Officer | J | Common Stock | 62815 | $0.00 | 148,533.0000 | 6,102,560 | 73.28% | 1.03% |
| Dec. 31, 2025 | Monopar Therapeutics | $MNPR | Robinson Chandler | Chief Executive Officer | M | Restricted Stock Unit | 8724 | $0.00 | 113,008.0000 | 6,662,930 | 7.17% | 0.13% |
| Dec. 31, 2025 | Monopar Therapeutics | $MNPR | Robinson Chandler | Chief Executive Officer | M | Common Stock | 8724 | $0.00 | 360,302.0000 | 6,662,930 | 2.48% | 0.13% |
| Dec. 31, 2025 | Monopar Therapeutics | $MNPR | Robinson Chandler | Chief Executive Officer | F | Common Stock | 2558 | $65.30 | 357,744.0000 | 6,662,930 | 0.71% | 0.04% |
| Dec. 2, 2025 | Monopar Therapeutics | $MNPR | Robinson Chandler | Chief Executive Officer | A | Stock Options | 16753 | $0.00 | 16,753.0000 | 6,662,930 | 9999.99% | 0.25% |
| Dec. 2, 2025 | Monopar Therapeutics | $MNPR | Robinson Chandler | Chief Executive Officer | A | Restricted Stock Units | 49133 | $0.00 | 121,732.0000 | 6,662,930 | 67.68% | 0.74% |
| Sept. 30, 2025 | Monopar Therapeutics | $MNPR | Robinson Chandler | Chief Executive Officer | F | Common Stock | 2646 | $81.67 | 351,578.0000 | 6,102,560 | 0.75% | 0.04% |
| Sept. 30, 2025 | Monopar Therapeutics | $MNPR | Robinson Chandler | Chief Executive Officer | M | Common Stock | 8726 | $0.00 | 354,224.0000 | 6,102,560 | 2.53% | 0.14% |
| Sept. 30, 2025 | Monopar Therapeutics | $MNPR | Robinson Chandler | Chief Executive Officer | M | Restricted Stock Units | 8726 | $0.00 | 72,599.0000 | 6,102,560 | 10.73% | 0.14% |
| July 14, 2025 | Monopar Therapeutics | $MNPR | Robinson Chandler | Chief Executive Officer | X | Common Stock | 16800 | $0.01 | 912,527.0000 | 6,102,560 | 1.88% | 0.28% |
| July 14, 2025 | Monopar Therapeutics | $MNPR | Robinson Chandler | Chief Executive Officer | S | Common Stock | 16800 | $40.00 | 895,727.0000 | 6,102,560 | 1.84% | 0.28% |
| July 14, 2025 | Monopar Therapeutics | $MNPR | Robinson Chandler | Chief Executive Officer | X | Stock Options | 16800 | $0.00 | 0.0000 | 6,102,560 | 100.00% | 0.28% |
| June 30, 2025 | Monopar Therapeutics | $MNPR | Robinson Chandler | Chief Executive Officer | F | Common Stock | 5865 | $35.78 | 895,727.0000 | 6,102,560 | 0.65% | 0.10% |
| June 30, 2025 | Monopar Therapeutics | $MNPR | Robinson Chandler | Chief Executive Officer | M | Restricted Stock Units | 13344 | $0.00 | 81,325.0000 | 6,102,560 | 14.10% | 0.22% |
| June 30, 2025 | Monopar Therapeutics | $MNPR | Robinson Chandler | Chief Executive Officer | M | Common Stock | 13344 | $0.00 | 901,592.0000 | 6,102,560 | 1.50% | 0.22% |
| March 31, 2025 | Monopar Therapeutics | $MNPR | Robinson Chandler | Chief Executive Officer | F | Common Stock | 1204 | $36.41 | 921,582.0000 | 6,102,560 | 0.13% | 0.02% |
| March 31, 2025 | Monopar Therapeutics | $MNPR | Robinson Chandler | Chief Executive Officer | M | Common Stock | 4106 | $0.00 | 922,786.0000 | 6,102,560 | 0.45% | 0.07% |
| March 31, 2025 | Monopar Therapeutics | $MNPR | Robinson Chandler | Chief Executive Officer | M | Restricted Stock Units | 4106 | $0.00 | 94,669.0000 | 6,102,560 | 4.16% | 0.07% |
| March 4, 2025 | Monopar Therapeutics | $MNPR | Robinson Chandler | Chief Executive Officer | F | Common Stock | 1759 | $31.70 | 918,680.0000 | 6,102,560 | 0.19% | 0.03% |
| March 4, 2025 | Monopar Therapeutics | $MNPR | Robinson Chandler | Chief Executive Officer | M | Common Stock | 6002 | $0.00 | 920,439.0000 | 6,102,560 | 0.66% | 0.10% |
| March 4, 2025 | Monopar Therapeutics | $MNPR | Robinson Chandler | Chief Executive Officer | M | Restricted Stock Units | 6002 | $0.00 | 98,775.0000 | 6,102,560 | 5.73% | 0.10% |
| March 4, 2025 | Monopar Therapeutics | $MNPR | Robinson Chandler | Chief Executive Officer | A | Restricted Stock Units | 79899 | $0.00 | 104,777.0000 | 6,102,560 | 321.16% | 1.31% |
| March 4, 2025 | Monopar Therapeutics | $MNPR | Robinson Chandler | Chief Executive Officer | A | Stock Options | 85759 | $0.00 | 85,759.0000 | 6,102,560 | 9999.99% | 1.41% |
| Dec. 31, 2024 | Monopar Therapeutics | $MNPR | Robinson Chandler | Chief Executive Officer | F | Common Stock | 2209 | $22.00 | 914,437.0000 | 3,520,427 | 0.24% | 0.06% |
| Dec. 31, 2024 | Monopar Therapeutics | $MNPR | Robinson Chandler | Chief Executive Officer | M | Restricted Stock Units | 4895 | $0.00 | 24,879.0000 | 3,520,427 | 16.44% | 0.14% |
| Dec. 31, 2024 | Monopar Therapeutics | $MNPR | Robinson Chandler | Chief Executive Officer | M | Common Stock | 4895 | $0.00 | 916,646.0000 | 3,520,427 | 0.54% | 0.14% |
| Sept. 30, 2024 | Monopar Therapeutics | $MNPR | Robinson Chandler | Chief Executive Officer | M | Common Stock | 4895 | $0.00 | 913,669.0000 | 3,520,427 | 0.54% | 0.14% |
| Sept. 30, 2024 | Monopar Therapeutics | $MNPR | Robinson Chandler | Chief Executive Officer | F | Common Stock | 1918 | $6.74 | 911,751.0000 | 3,520,427 | 0.21% | 0.05% |
| Sept. 30, 2024 | Monopar Therapeutics | $MNPR | Robinson Chandler | Chief Executive Officer | M | Restricted Stock Units | 4895 | $0.00 | 29,774.0000 | 3,520,427 | 14.12% | 0.14% |
| June 30, 2024 | Monopar Therapeutics | $MNPR | Robinson Chandler | Chief Executive Officer | F | Common Stock | 8684 | $0.73 | 4,543,862.6800 | 2,980,900 | 0.19% | 0.29% |
| June 30, 2024 | Monopar Therapeutics | $MNPR | Robinson Chandler | Chief Executive Officer | M | Restricted Stock Units | 24476 | $0.00 | 173,335.0000 | 2,980,900 | 12.37% | 0.82% |
| June 30, 2024 | Monopar Therapeutics | $MNPR | Robinson Chandler | Chief Executive Officer | M | Common Stock | 24476 | $0.00 | 4,552,546.6800 | 2,980,900 | 0.54% | 0.82% |
| May 28, 2024 | Monopar Therapeutics | $MNPR | Robinson Chandler | Chief Executive Officer | X | Stock Options | 84000 | $0.00 | 0.0000 | 2,980,900 | 100.00% | 2.82% |
| May 28, 2024 | Monopar Therapeutics | $MNPR | Robinson Chandler | Chief Executive Officer | X | Common Stock | 84000 | $0.00 | 4,528,070.6800 | 2,980,900 | 1.89% | 2.82% |
| March 31, 2024 | Monopar Therapeutics | $MNPR | Robinson Chandler | Chief Executive Officer | F | Common Stock | 7172 | $0.68 | 4,444,070.6800 | 2,980,900 | 0.16% | 0.24% |
| March 31, 2024 | Monopar Therapeutics | $MNPR | Robinson Chandler | Chief Executive Officer | M | Common Stock | 24474 | $0.00 | 4,451,242.6800 | 2,980,900 | 0.55% | 0.82% |
| March 31, 2024 | Monopar Therapeutics | $MNPR | Robinson Chandler | Chief Executive Officer | M | Restricted Stock Units | 24474 | $0.00 | 197,811.0000 | 2,980,900 | 11.01% | 0.82% |
| Jan. 1, 2024 | Monopar Therapeutics | $MNPR | Robinson Chandler | Chief Executive Officer | M | Restricted Stock Units | 6724 | $0.00 | 222,285.0000 | 2,980,900 | 2.94% | 0.23% |
| Jan. 1, 2024 | Monopar Therapeutics | $MNPR | Robinson Chandler | Chief Executive Officer | M | Common Stock | 6724 | $0.00 | 8,707,035.5600 | 2,980,900 | 0.08% | 0.23% |
| Jan. 1, 2024 | Monopar Therapeutics | $MNPR | Robinson Chandler | Chief Executive Officer | F | Common Stock | 2327 | $0.34 | 8,704,708.5600 | 2,980,900 | 0.03% | 0.08% |
| Dec. 31, 2023 | Monopar Therapeutics | $MNPR | Robinson Chandler | Chief Executive Officer | M | Restricted Stock Units | 24474 | $0.00 | 229,009.0000 | 0 | 9.66% | 0.00% |
| Dec. 31, 2023 | Monopar Therapeutics | $MNPR | Robinson Chandler | Chief Executive Officer | M | Common Stock | 24474 | $0.00 | 8,708,780.5600 | 0 | 0.28% | 0.00% |
| Dec. 31, 2023 | Monopar Therapeutics | $MNPR | Robinson Chandler | Chief Executive Officer | F | Common Stock | 8469 | $0.34 | 8,700,311.5600 | 0 | 0.10% | 0.00% |
| Sept. 30, 2023 | Monopar Therapeutics | $MNPR | Robinson Chandler | Chief Executive Officer | F | Common Stock | 7172 | $0.62 | 4,406,366.6800 | 0 | 0.16% | 0.00% |
| Sept. 30, 2023 | Monopar Therapeutics | $MNPR | Robinson Chandler | Chief Executive Officer | M | Restricted Stock Units | 24474 | $0.00 | 253,483.0000 | 0 | 8.80% | 0.00% |
| Sept. 30, 2023 | Monopar Therapeutics | $MNPR | Robinson Chandler | Chief Executive Officer | M | Common Stock | 24474 | $0.00 | 4,413,538.6800 | 0 | 0.56% | 0.00% |
| June 30, 2023 | Monopar Therapeutics | $MNPR | Robinson Chandler | Chief Executive Officer | M | Common Stock | 35039 | $0.00 | 4,399,333.6800 | 0 | 0.80% | 0.00% |
| June 30, 2023 | Monopar Therapeutics | $MNPR | Robinson Chandler | Chief Executive Officer | F | Common Stock | 10269 | $0.86 | 4,389,064.6800 | 0 | 0.23% | 0.00% |
| June 30, 2023 | Monopar Therapeutics | $MNPR | Robinson Chandler | Chief Executive Officer | M | Restricted Stock Units | 35039 | $0.00 | 277,957.0000 | 0 | 11.19% | 0.00% |
| March 31, 2023 | Monopar Therapeutics | $MNPR | Robinson Chandler | Chief Executive Officer | M | Restricted Stock Units | 13911 | $0.00 | 312,996.0000 | 0 | 4.26% | 0.00% |
| March 31, 2023 | Monopar Therapeutics | $MNPR | Robinson Chandler | Chief Executive Officer | F | Common Stock | 4286 | $1.39 | 4,364,294.6800 | 0 | 0.10% | 0.00% |
| March 31, 2023 | Monopar Therapeutics | $MNPR | Robinson Chandler | Chief Executive Officer | M | Common Stock | 13911 | $0.00 | 4,368,580.6800 | 0 | 0.32% | 0.00% |
| Feb. 1, 2023 | Monopar Therapeutics | $MNPR | Robinson Chandler | Chief Executive Officer | A | Restricted Stock Units | 169012 | $0.00 | 326,907.0000 | 0 | 107.04% | 0.00% |
| Feb. 1, 2023 | Monopar Therapeutics | $MNPR | Robinson Chandler | Chief Executive Officer | A | Stock Options | 221839 | $0.00 | 221,839.0000 | 0 | 9999.99% | 0.00% |
| Dec. 31, 2022 | Monopar Therapeutics | $MNPR | Robinson Chandler | Chief Executive Officer | M | Restricted Stock Units | 13912 | $0.00 | 151,171.0000 | 0 | 8.43% | 0.00% |
| Dec. 31, 2022 | Monopar Therapeutics | $MNPR | Robinson Chandler | Chief Executive Officer | M | Common Stock | 13912 | $0.00 | 8,633,027.5600 | 0 | 0.16% | 0.00% |
| Jan. 1, 2023 | Monopar Therapeutics | $MNPR | Robinson Chandler | Chief Executive Officer | M | Restricted Stock Units | 6723 | $0.00 | 6,724.0000 | 0 | 50.00% | 0.00% |
| Jan. 1, 2023 | Monopar Therapeutics | $MNPR | Robinson Chandler | Chief Executive Officer | F | Common Stock | 2327 | $2.37 | 8,632,609.5600 | 0 | 0.03% | 0.00% |
| Jan. 1, 2023 | Monopar Therapeutics | $MNPR | Robinson Chandler | Chief Executive Officer | M | Common Stock | 6723 | $0.00 | 8,634,936.5600 | 0 | 0.08% | 0.00% |
| Dec. 31, 2022 | Monopar Therapeutics | $MNPR | Robinson Chandler | Chief Executive Officer | F | Common Stock | 4814 | $2.37 | 8,628,213.5600 | 0 | 0.06% | 0.00% |